Validation of a High-Throughput Screening Assay for Identification of Adjunctive and Directly Acting Antimicrobials Targeting Carbapenem-Resistant Enterobacteriaceae

Assay and Drug Development Technologies

Volumn 14, Issue 3, 2016, Pages 194-206

  Smith, Kenneth P ^a   Kirby, James E ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMPICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; CALMIDAZOLIUM; CARBAPENEM; CEPHALOSPORIN DERIVATIVE; COLISTIN; COTRIMOXAZOLE; DIPHENYLIODONIUM SALT; DOXYCYCLINE; GENTAMICIN; MEROPENEM; MINOCYCLINE; NITROFURANTOIN; QUINOLONE DERIVATIVE; SPECTINOMYCIN; TIGECYCLINE; TOBRAMYCIN; TRICLOSAN; ZIDOVUDINE; ANTIINFECTIVE AGENT; CARBAPENEM DERIVATIVE; MOLECULAR LIBRARY;

ARTICLE; BACTERIAL GROWTH; BACTERIUM IDENTIFICATION; CARBAPENEM RESISTANT ENTEROBACTERIACEAE; CONTROLLED STUDY; DOSE RESPONSE; FRACTIONAL INHIBITORY CONCENTRATION INDEX; GONORRHEA; HIGH THROUGHPUT SCREENING; HUMAN IMMUNODEFICIENCY VIRUS; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHENOTYPE; ANALYSIS; ANTIBIOTIC RESISTANCE; DRUG EFFECTS; ENTEROBACTERIACEAE; GROWTH, DEVELOPMENT AND AGING; MICROBIAL SENSITIVITY TEST; MOLECULAR LIBRARY; PHARMACOLOGY; STRUCTURE ACTIVITY RELATION; VALIDATION STUDY;

ANTI-BACTERIAL AGENTS; CARBAPENEMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, BACTERIAL; ENTEROBACTERIACEAE; HIGH-THROUGHPUT SCREENING ASSAYS; MICROBIAL SENSITIVITY TESTS; SMALL MOLECULE LIBRARIES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84964818009     PISSN: 1540658X     EISSN: 15578127     Source Type: Journal    
DOI: 10.1089/adt.2016.701     Document Type: Article

References (55)

1. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB: Nosocomial bloodstream infections in US hospitals: Analysis of 24, 179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004;39: 309-317.
2. Sanchez GV, Master RN, Karlowsky JA, Bordon JM: In vitro antimicrobial resistance of urinary Escherichia coli isolates among U.S. outpatients from 2000 to 2010. Antimicrob Agents Chemother 2012;56:2181-2183.
3. Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009;48:1-12.
4. Morrill HJ, Pogue JM, Kaye KS, LaPlante KL: Treatment options for carbapenem-resistant enterobacteriaceae infections. Open Forum Infect Dis 2015;2:ofv050.
5. Falagas ME, Tansarli GS, Karageorgopoulos DE, Vardakas KZ: Deaths attributable to carbapenem-resistant Enterobacteriaceae infections. Emerg Infect Dis 2014;20:1170-1175.
6. Thaden JT, Lewis SS, Hazen KC, et al:. Rising rates of carbapenem-resistant enterobacteriaceae in community hospitals: a mixed-methods review of epidemiology and microbiology practices in a network of community hospitals in the southeastern United States. Infect Control Hosp Epidemiol 2014;35:978-983.
7. Bratu S, Landman D, Haag R, et al:. Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: A new threat to our antibiotic armamentarium. Arch Intern Med 2005;165:1430-1435.
8. Centers for Disease Control and Prevention: Vital signs: Carbapenem-resistant Enterobacteriaceae. MMWR Morb Mortal Wkly Rep 2013;62:165-170.
9. Centers for Disease Control and Prevention: Antibiotic/antimicrobial resistance biggest threats, www.cdc.gov/drugresistance/biggest-threats.html (accessed December 31, 2015).
10. Linden P: Safety profile of meropenem: An updated review of over 6, 000 patients treated with meropenem. Drug Saf 2007;30:657-668.
11. Esterly JS, Wagner J, McLaughlin MM, Postelnick MJ, Qi C, Scheetz MH: Evaluation of clinical outcomes in patients with bloodstream infections due to Gram-negative bacteria according to carbapenem MIC stratification. Antimicrob Agents Chemother 2012;56:4885-4890.
12. Clinical and Laboratory Standards Institute: Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Fifth Informational Supplement. CLSI Document M100-S25. Clinical and Laboratory Standards Institute, Wayne, PA, 2015.
13. Davies TA, Marie Queenan A, Morrow BJ, et al. Longitudinal survey of carbapenem resistance and resistance mechanisms in Enterobacteriaceae and non-fermenters from the USA in 2007-09. J Antimicrob Chemother 2011;66: 2298-2307.
14. Navon-Venezia S, Chmelnitsky I, Leavitt A, Schwaber MJ, Schwartz D, Carmeli Y: Plasmid-mediated imipenem-hydrolyzing enzyme KPC-2 among multiple earbapenem-resistant Escherichia coli clones in Israel. Antimicrob Agents Chemother 2006;50:3098-3101.
15. Lewis K: Platforms for antibiotic discovery. Nat Rev Drug Disco 2013;12:371-387.
16. Kitchel B, Rasheed JK, Patel JB, et al.: Molecular epidemiology of KPC-producing Klebsiella pneumoniae isolates in the United States: Clonal expansion of multilocus sequence type 258. Antimicrob Agents Chemother 2009;53:3365-3370.
17. INSTITUT Pasteur MLSTand whole genome MLST databases: Klebsiella sequence typing home page, http://bigsdb.web.pasteur.fr/klebsiella/klebsiella.html (accessed February 25, 2016).
18. Clinical and Laboratory Standards Institute: Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard-Tenth Edition. CLSI Document/W07-/U0.Clinical and Laboratory Standards Institute, Wayne, PA, 2015.
19. Chiaraviglio L, Kirby JE: High-throughput intracellular antimicrobial susceptibility testing of Legionella pneumophila. Antimicrob Agents Chemother 2015;59:7517-7529.
20. Hitchings GH, Falco EA, Vanderwerff H, Russell PB, Elion GB: Antagonists of nucleic acid derivatives. VII. 2, 4-Diaminopyrimidines. J Biol Chem 1952;199: 43-56.
21. Malo N, Hanley JA, Cerquozzi S, Pelletier J, Nadon R: Statistical practice in high-throughput screening data analysis. Nat Biotechnol 2006;24: 167-175.
22. Harbut MB, Vilcheze C, Luo X, et al. Auranofin exerts broad-spectrum bactericidal activities by targeting thiol-redox homeostasis. Proc Natl Acad Sci USA 2015;112:4453-4458.
23. Davis JW, Libke KG, Kornegay ET: Carbadox in the prevention of experimentally induced swine dysentery. J Am Vet Med Assoc 1968;153:1181-1184.
24. Finkelstein RA, Raungthum J: A laboratory evaluation of clioquinol as a prophylactic against cholera. Bull World Health Organ 1968;38:803-807.
25. Silvernale JN, Joswick HL, Corner TR, Gerhardt P: Antimicrobial actions of hexachlorophene: Cytological manifestations. J Bacteriol 1971;108:482-491.
26. Weinberg ED: Antimicrobial activities of biguanides. Ann N Y Acad Sci 1968;148:587-600.
27. Tan X, Chu CK, Boudinot FD: Development and optimization of anti-HIV nucleoside analogs and prodrugs: A review of their cellular pharmacology, structure-activity relationships and pharmacokinetics. Adv Drug Deliv Rev 1999;39:117-151.
28. Unemo M: Current and future antimicrobial treatment of gonorrhoea-The rapidly evolving Neisseria gonorrhoeae continues to challenge. BMC Infect Dis 2015;15:364.
29. Kusumi R, Metzler C, Fass R: Pharmacokinetics of spectinomycin in volunteers with renal insufficiency. Chemotherapy 1981;27:95-98.
30. McArthur AG, Waglechner N, Nizam F, et al.: The comprehensive antibiotic resistance database. Antimicrob Agents Chemother 2013;57: 3348-3357.
31. Watkins RR, Papp-Wallace KM, Drawz SM, Bonomo RA: Novel beta-lactamase inhibitors: A therapeutic hope against the scourge of multidrug resistance. Front Microbiol 2013;4:392.
32. Efficacy, Safety, Tolerability of Carbavance Compared to Best Available Therapy in Serious Infections Due to Carbapenem Resistant Enterobacteriaceae, in Adults. https://clinicaltrials.gov/ct2/show/NCT02168946 (accessed January 11, 2016).
33. Bulik CC, Nicolau DP: Double-carbapenem therapy for carbapenemase-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 2011;55: 3002-3004.
34. Ceccarelli G, Falcone M, Giordano A, et al. Successful ertapenem-doripenem combination treatment of bacteremic ventilator-associated pneumonia due to colistin-resistant KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 2013;57:2900-2901.
35. Lim TP, Cai Y, Hong Y, et al:. In vitro pharmacodynamics of various antibiotics in combination against extensively drug-resistant Klebsiella pneumoniae. Antimicrob Agents Chemother 2015;59:2515-2524.
36. Wignall GR, Goneau LW, Chew BH, Denstedt JD, Cadieux PA: The effects of triclosan on uropathogen susceptibility to clinically relevant antibiotics. J Endourol 2008;22:2349-2356.
37. Pillai K, Eliopoulos G: Antimicrobial combinations. In: Antibiotics in Laboratory Medicine. Lorian V, (ed.), pp. 365-440. Lippincot, Williams and Wilkins, Philadelphia, PA, 2005.
38. Yamamoto K, Kitayama T, Ishida N, et al.: Identification and characterization of a potent antibacterial agent, NH125 against drug-resistant bacteria. Biosci Biotechnol Biochem 2000;64:919-923.
39. Kim W, Conery AL, Rajamuthiah R, Fuchs BB, Ausubel FM, Mylonakis E: Identification of an antimicrobial agent effective against methicillin-resistant Staphylococcus aureus persisters using a fluorescence-based screening strategy. PLoS One 2015;10:e0127640.
40. Riganti C, Gazzano E, Polimeni M, Costamagna C, Bosia A, Ghigo D: Diphenyleneiodonium inhibits the cell redox metabolism and induces oxidative stress. J Biol Chem 2004;279:47726-47731.
41. Stuehr DJ, Fasehun OA, Kwon NS, et al.: Inhibition of macrophage and endothelial cell nitric oxide synthase by diphenyleneiodonium and its analogs. FASEBJ 1991;5:98-103.
42. Mitsuya H, Broder S: Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type lll/lymphadenopathy-associated virus (HTLV-III/LAV) by 2', 3'-dideoxynucleosides. Proc Natl Acad Sci USA 1986; 83:1911-1915.
43. Furman PA, Fyfe JA, St Clair MH, et al.: Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci USA 1986;83:8333-8337.
44. Elwell LP, Ferone R, Freeman GA, et al.: Antibacterial activity and mechanism of action of 3'-azido-3'-deoxythymidine (BW A509U). Antimicrob Agents Chemother 1987;31:274-280.
45. Lewin CS, Allen R, Amyes SG: Zidovudine-resistance in Salmonella typhimurium and Escherichia coli. J Antimicrob Chemother 1990;25:706-708.
46. Lewin CS, Watt B, Paton R, Amyes SG: Isolation of zidovudine resistant Escherichia coli from AIDS patients. FEMS Microbiol Lett 1990;58:141-143.
47. Sandrini MP, Clausen AR, On SL, Aarestrup FM, Munch-Petersen B, Piskur J: Nucleoside analogues are activated by bacterial deoxyribonucleoside kinases in a species-specific manner. J Antimicrob Chemother 2007;60:510-520.
48. Keith BR, White G, Wilson HR: In vivo efficacy of zidovudine (3'-azido-3'-deoxythymidine) in experimental gram-negative-bacterial infections. Antimicrob Agents Chemother 1989;33:479-483.
49. Schroeter AL, Reynolds GH, Holmes KK, Pyke T, Wiesner PJ: Spectinomycin in the treatment of gonorrhea. J Am Venereal Dis Assoc 1975;1:139-145.
50. Cload PA: A review of the pharmacokinetics of zidovudine in man. J Infect 1989;18 Suppl 1:15-21.
51. Akiyoshi M, Yano S, Ikeda T: Ototoxicity of spectinomycin (author's transl). Jpn J Antibiot 1976;29:771-782.
52. Trobicin™ spectinomycin for injectable suspension, USP. www.accessdata.fda.gov/drugsatfda-docs/label/2012/050347s060lbl.pdf (accessed January 11, 2016).
53. Matt T, Ng CL, Lang K, et al.: Dissociation of antibacterial activity and aminoglycoside ototoxicity in the 4-monosubstituted 2-deoxystreptamine apramycin. Proc Natl Acad Sci USA 2012;109:10984-10989.
54. Gonzalez LS, 3rd, Spencer JP: Aminoglycosides: A practical review. Am Earn Physician 1998;58:1811-1820.
55. Bradford PA, Petersen PJ, Young M, Jones CH, Tisehler M, O'Connell J: Tigeeyeline MIC testing by broth dilution requires use of fresh medium or addition of the bioeatalytic oxygen-reducing reagent oxyrase to standardize the test method. Antimicrob Agents Chemother 2005;49:3903-3909.